EP0335017A3 - Novel use of trazodone - Google Patents

Novel use of trazodone Download PDF

Info

Publication number
EP0335017A3
EP0335017A3 EP88202680A EP88202680A EP0335017A3 EP 0335017 A3 EP0335017 A3 EP 0335017A3 EP 88202680 A EP88202680 A EP 88202680A EP 88202680 A EP88202680 A EP 88202680A EP 0335017 A3 EP0335017 A3 EP 0335017A3
Authority
EP
European Patent Office
Prior art keywords
trazodone
novel use
pharmaceutical compositions
release
infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88202680A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0335017A2 (en
Inventor
Bruno Silvestrini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of EP0335017A2 publication Critical patent/EP0335017A2/en
Publication of EP0335017A3 publication Critical patent/EP0335017A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP88202680A 1987-12-02 1988-11-24 Novel use of trazodone Withdrawn EP0335017A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8722856A IT1233412B (it) 1987-12-02 1987-12-02 Uso del trazodone
IT2285687 1987-12-02

Publications (2)

Publication Number Publication Date
EP0335017A2 EP0335017A2 (en) 1989-10-04
EP0335017A3 true EP0335017A3 (en) 1990-07-25

Family

ID=11201237

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88202680A Withdrawn EP0335017A3 (en) 1987-12-02 1988-11-24 Novel use of trazodone

Country Status (4)

Country Link
US (1) US4906632A (it)
EP (1) EP0335017A3 (it)
JP (1) JPH01211522A (it)
IT (1) IT1233412B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
ITMI20071573A1 (it) * 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂
WO2025107056A1 (en) * 2023-11-23 2025-05-30 Sanofi Medley Farmaceutica Ltda Extended-release pharmaceutical composition and preparation process

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154832A (en) * 1974-08-26 1979-05-15 Bruno Silvestrini Novel treatment for acute organic cerebral syndromes (strokes)
FR2511869A1 (fr) * 1981-08-27 1983-03-04 Coughlin Shaun Composition pharmaceutique pour le traitement de l'atherosclerose
GB2207052A (en) * 1987-07-21 1989-01-25 Roussel Lab Ltd Controlled release osmotic device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154832A (en) * 1974-08-26 1979-05-15 Bruno Silvestrini Novel treatment for acute organic cerebral syndromes (strokes)
FR2511869A1 (fr) * 1981-08-27 1983-03-04 Coughlin Shaun Composition pharmaceutique pour le traitement de l'atherosclerose
GB2207052A (en) * 1987-07-21 1989-01-25 Roussel Lab Ltd Controlled release osmotic device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CURRENT THERAPEUTIC RESEARCH, vol. 18, no. 3, September 1975, pages 410-416, Therapeutic Research Press, Inc.; L. ALLORI et al.: "Experimental and clinical data indicating a potential use of trazodone in acute stroke" *
STROKE, vol. 17, no. 5, 1986, pages 953-956; M. RAMIREZ-LESSEPAS et al.: "Failure of central nervous system serotonin blockage to influence outcome in acute cerebral infarction. A double blind randomized trial" *
THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, 14th edition 1982, pages 1324-1334, chapter 127: "Cerebrovascular disease", edited by R. Berkow et al., Merck & Co., Inc., Rahway, N.Y., US *

Also Published As

Publication number Publication date
IT1233412B (it) 1992-03-30
US4906632A (en) 1990-03-06
JPH01211522A (ja) 1989-08-24
IT8722856A0 (it) 1987-12-02
EP0335017A2 (en) 1989-10-04

Similar Documents

Publication Publication Date Title
AR243378A1 (es) Procedimiento para preparar una formulacion farmaceutica de liberacion prolongada.
NZ219380A (en) (n-piperidinyl)- and (n-piperazinyl)-methylazole derivatives and pharmaceutical compositions
PH25376A (en) Oral sustained release acetaminophen formulation, process
GB8926843D0 (en) Sustained release pharmaceutical compositions
NZ225101A (en) Sustained release composition
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
CA2135751A1 (en) 4-Mercaptoacetylamino-[2] Benzazepinone(3) Derivatives, and Use as Enkephalinase Inhibitors
HUT46531A (en) Process for producing retard tabletted pharmaceutical compositions
NZ226845A (en) 2', 3'-dideoxy-2'-fluoronucleosides; pharmaceutical compositions and processes for their preparation
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
EP0335017A3 (en) Novel use of trazodone
IL77322A (en) Sustained release pharmaceutical compositions containing 1,3-dimethylxanthine and processes for the preparation thereof
CA2041818A1 (en) Separation of enantiomers of cimaterol, (-)-cimaterol and the use thereof as pharmaceutical compositions or as performance enhancers
NZ232946A (en) Preparation of crystalline 17alpha-hydroxy-7alpha methyl-19-nor-17-pregn-5
IL85945A0 (en) Pharmaceutical compositions containing 2'-fluoronucleosides and derivatives thereof,certain such novel compounds and their preparation
AP9000223A0 (en) Novel aryloxy alcoyl benzenes,process for their preparation as the pharmaceutical composition containing them
ZA904925B (en) Sustained release pharmaceutical compositions
IL87563A0 (en) Isoxazole-beta-carboline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2195893B (en) Sustained release pharmaceutical compositions
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
GR3004863T3 (it)
EP0291957A3 (en) Nitrogen containing derivatives of epipodophyllotoxin glucosides, a process for preparing them and pharmaceutical compositions
EP0297594A3 (en) Novel 3',4'-dinitrogen substituted epipodophyllotoxin glucoside derivatives
AU5992990A (en) 14,17alpha-etheno- and -ethanoestratrienes, processes for the preparation of these compounds, as well as their use for the production of medicinal agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901205

17Q First examination report despatched

Effective date: 19910802

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19911213